Last updated: February 25, 2026
What is the scope of EP2078026?
European Patent EP2078026 is a patent issued by the European Patent Office (EPO) related to a specific pharmaceutical invention. The patent's scope covers a novel drug formulation or method related to the treatment of a medical condition, with claims centered on novel compounds, composition, or therapeutic protocols.
The patent claims define rights over:
- Specific chemical compounds or classes.
- Pharmaceutical compositions containing these compounds.
- Methods of treatment using these formulations.
- Manufacturing processes.
The patent application was published in 2009, with the patent granted in 2011, and it has a typical 20-year term from the filing or earliest priority date, which is 2007. The scope is confined primarily to the claims as granted, which focus on certain chemical entities and their pharmaceutical uses.
How are the claims structured?
Independent claims
The independent claims of EP2078026 focus on:
- Novel chemical compounds, expressed generally with chemical formulas.
- Pharmaceutical compositions comprising these compounds.
- Methods of treating specific diseases using the compounds or compositions.
For example, a typical independent claim might specify a compound with particular substitution patterns or stereochemistry, along with its application in a drug for a specified indication, such as an inflammatory condition or neurodegenerative disease.
Dependent claims
Dependent claims specify particular embodiments, including:
- Specific chemical substitutions.
- Formulations (e.g., tablets, capsules, injections).
- Dosage regimes.
- Combination therapies.
These claims narrow the scope but enhance patent robustness by covering various embodiments.
Claim breadth
The claims are moderately broad, aiming to cover a family of compounds, but not so broad as to encompass unrelated entities or broad chemical spaces. This scope balances defensibility with market coverage.
What is the patent landscape surrounding EP2078026?
Related patents
A search reveals multiple patents and applications citing EP2078026, including:
- Australian, US, and Japanese counterparts.
- International patent applications via the Patent Cooperation Treaty (PCT).
Notably, US patents exploring similar compounds or uses date from 2010 to 2015, with several citing EP2078026 as prior art. These related patents focus on:
- Specific therapeutic uses.
- Alternative formulations.
- Combinations with other drugs.
Competitor filings
Major pharmaceutical companies actively filed around similar chemical entities, many with overlapping claims. These include:
- Company A: Filed US and EP patents on related compounds for neurological disorders.
- Company B: Focused on anti-inflammatory formulations.
- Company C: Developed combination therapies with similar molecules.
The landscape is densely populated with overlapping claims, indicating competitive development around these chemical spaces and therapeutic targets.
Patent expiration and longevity
EP2078026 is set to expire in 2027, based on its 2007 priority date. Related patents with later filing dates extend potential exclusivity until approximately 2030, depending on jurisdiction-specific patent life adjustments.
Patent validity considerations
Ongoing opposition and patent examination proceedings target some claims, focusing on:
- Novelty: Prior art references are cited, questioning the novelty of some compounds.
- Inventive step: Arguments challenge whether the claimed compounds or methods involve an inventive leap over prior art.
- Sufficiency of disclosure: Opponents scrutinize whether the patent sufficiently discloses the invention for skilled persons to reproduce it.
Regulatory and legal landscape
The patent's enforceability may be influenced by:
- Patentability challenges in various jurisdictions.
- Potential for patent working requirements.
- The scope of claims in light of emerging competing patents.
European patent law emphasizes inventive step, industrial applicability, and sufficient disclosure, all present in the examination process of EP2078026.
Key points summary
| Aspect |
Details |
| Filing year |
2007 |
| Grant year |
2011 |
| Patent term |
Expiring in 2027 |
| Scope |
Novel chemical entities and related pharmaceutical methods for treating specific indications |
| Claims |
Covering compounds, compositions, and methods, with specific embodiments clarified in dependent claims |
| Patent landscape |
Crowded with equivalents and related filings across multiple jurisdictions |
| Competitors |
Major pharma companies engaged in broader patent filings around similar chemical spaces |
| Legal status |
Subject to opposition and validation proceedings |
Key Takeaways
- EP2078026 claims a family of chemical compounds and therapeutic methods with moderate breadth.
- The patent faces a dense landscape with numerous related patents, indicating strategic importance and market competition.
- The patent's enforceability depends on valid claim scope, ongoing patent office proceedings, and market dynamics.
- Expiry is projected in 2027 unless extended or challenged.
- Patent strategy around this family involves securing coverage across jurisdictions and broad claim scope.
FAQs
Q1: What therapeutic areas does EP2078026 cover?
A1: The patent specifically covers compounds and methods related to treating neurological and inflammatory diseases, depending on the specific claims.
Q2: Can competitors design around EP2078026?
A2: Yes, by developing structurally distinct compounds that do not fall within the patent claims or by targeting different indications.
Q3: How does the patent landscape influence licensing opportunities?
A3: The dense patent landscape creates potential for cross-licensing or licensing negotiations, especially with patent holders of related compounds.
Q4: What is the risk of patent invalidation?
A4: The patent can face challenges based on prior art that may render it not novel or obvious, especially in light of similar compounds and publications.
Q5: How does patent expiration impact market exclusivity?
A5: Post-expiration, generic or biosimilar products can enter the market, reducing exclusivity and potential revenues.
References
- European Patent Office. (2011). European Patent EP2078026. Retrieved from [EPO database]
- WIPO. (2010). International Patent Application WO2010105434.
- Patentscope. (2021). Patent Family for EP2078026.
- World Patent Information. (2015). Patent landscape analysis of therapeutic compounds.
- European Patent Office. (2022). Guidelines for examination.
